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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comprocedural complication. Multiple logistic regression analysis showed that the pres-
ence of peripheral vascular disease (PVD) (p¼0.024, OR¼1.9), DM (p¼0.002,
OR¼2.2), ACS presentation (p¼0.013, OR¼1.9) and SYNTAX score (p< 0.001,
OR¼1.047) had a signiﬁcant impact on MACE.
Conclusions: RA is a complex but safe procedure typically performed in elderly high-
risk patients with calciﬁed lesions. Higher syntax scores >22 and>32 were associated
with higher rates of death, MI, TVR and ST. PVD, DM, ACS presentation and syntax
score are signiﬁcant predictors for MACE.Table 1. Outcomes by SYNTAX category.
SYNTAX22 SYNTAX>22 p-value SYNTAX32 SYNTAX>32 p-value
Total 334 181 443 72
Cardiac Death 12 (3.6%) 21 (11.6%) 0.001 21 (4.7%) 12 (16.7%) 0.001
Death 33 (9.9%) 37 (20.4%) 0.002 47 (10.6%) 23 (31.9%) <0.001
TVR 22 (6.6%) 17 (9.4%) 0.295 33 (7.4%) 6 (8.3%) 0.81
MI 25 (7.5%) 33 (18.2%) <0.001 41 (9.3%) 17 (23.6%) 0.001
Stent Thrombosis 0 (0%) 6 (3.3%) 0.002 4 (0.9%) 2 (2.8%) 0.199
Stroke 8 (2.5%) 7 (4.2%) 0.284 11 (2.6%) 4 (5.9%) 0.139
MACE 45 (13.5%) 51 (28.2%) <0.001 70 (15.8%) 26 (36.1%) <0.001
Vascular complications 7 (2.1%) 4 (2.2%) 1 10 (2.3%) 1 (1.4%) 1
Procedural
complications
16 (4.8%) 16 (8.8%) 0.085 22 (5.0%) 10 (13.9%) 0.008TCT-131
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Background: Percutaneous removal of atherosclerotic material using atherectomy
devices may offer an alternative approach for improving procedural success. The
TRUTH study (24 patients) evaluated the removal of plaque with the Orbital Athe-
rectomy System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN) by analyzing
changes in plaque volume/composition via an independent virtual histology (VH)-
intravascular ultrasound (IVUS) Core Laboratory at CRF.
Methods: Lesions in the superﬁcial femoral artery, popliteal, and/or tibioperoneal
trunk were treated with the OAS followed by adjunctive balloon angioplasty (BA).
IVUS images were collected during 1) pre-treatment; 2) post-OAS; and 3) post-BA.
Results: The mean age was 70.4 years and 36% of patients had a history of renal
insufﬁciency, diabetes (72%), hyperlipidemia (100%), hypertension (100%), and
smoking (84%). The mean lesion and calcium length assessed via angiography was
65.4+27.8mm and 55.431.6 mm, respectively. The baseline Rutherford Classiﬁcation
(RC) of 3 (96.0%) changed RC of 0 (100% asymptomatic) at 2 week follow-up. No
incidence of recoil, slow ﬂow/no reﬂow, ﬂow-limiting dissections or perforations were
reported. VH-IVUS analysis revealed that the minimum lumen area increased from 4.0
mm2 to 9.1 mm2 post-procedure (< 0.0001) accompanied with decrease of area stenosis
(Table). At the maximum calcium ablation site, the lumen area also increased and cal-
cium reduction was responsible for 86% [35%, 100%] of the lumen increase. The arc of
reverberation increased from 22 to 39 (p¼0.05) and the prevalence of convex shape of
calcium surface decreased indicating device-related modiﬁcation of calcium.Pre Post-OAS Post-BA
p-value
(overall)
p-value (pre vs
post-OAS)
Lesion analysis (n¼24 lesions)
Minimum lumen area, mm2 4.0 [2.2,
4.9]
4.7 [3.2,
5.9]
9.1 [7.8,
10.5]
<0.0001 0.072
Area stenosis, % 77 [61, 81] 64 [58, 77] 43 [27, 56] <0.0001 0.067
Mean vessel area, mm3/mm 31.4 [26.1,
35.2]
31.8 [25.9,
37.8]
34.5 [31.9,
40.3]
<0.0001 0.21
Mean lumen area, mm3/mm 8.5 [5.0,
9.9]
8.9 [8.1,
11.1]
12.9 [11.7,
15.2]
<0.0001 0.037
Mean plaque area, mm3/mm 22.1 [18.5,
28.1]
22.1 [18.1,
26.2]
21.9 [17.9,
25.3]
0.04 0.7
Calciﬁed plaque analysis (28 calciﬁed plaques)
Lumen area, mm2 6.2 [4.7,
8.7]
8.4 [6.4,
10.9]
12.2 [11.2,
14.9]
<0.0001 0.0013
Area stenosis, % 58 [29, 69] 38 [11, 45] 16 [10, 42] <0.0001 <0.0001
Convex shape of surface of
calcium, %
54 39 29 0.011 0.21
Reverberation, % 25 39 36 0.095 0.11
Arc of reverberation,  22 [18, 24] 39 [27, 60] 28 [20, 47] 0.43 0.05
% of Calcium Reduction out of
Lumen Gain
– 86 [35,100] – – –
OAS¼orbital atherectomy system; BA¼balloon angioplasty
B40 JACC Vol 64/11Conclusions: The orbital atherectomy system (OAS) is effective at reducing and
modifying calcium from lesions, resulting in low acute complications and improved
Rutherford Classiﬁcation.
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Background: Directional atherectomy is an endovascular therapy that is effective in
the treatment of diabetic and non-diabetic patients with peripheral artery disease
(PAD). This study was undertaken to assess the all-cause healthcare costs of direc-
tional atherectomy as well as other therapies used in treating diabetic patients with
PAD over 24-months post-treatment.
Methods: PAD patients were selected from a large claims database with 1 CPT code
for a lower extremity PAD procedure between 2005-2011. The date of the ﬁrst CPT
code was the index date. Patients were included with: 12-months of pre-index date
continuous medical and pharmacy eligibility; 1 PAD ICD-9-CM code within
6 months prior to the index date; 1 medical claim for Type 2 Diabetes Mellitus
during baseline; and 18 years of age on index date. Multivariate models to evaluate
risk of hospitalization during follow-up and all-cause health care cost at 24 months
were constructed, controlling for covariates.
Results: 8,121 patients had both diabetes and PAD, with a mean age of
67.6 years and 39% were female. Endovascular treatments received for PAD treat-
ments were: stent (26%), peripheral bypass (23%), PTA+stent (22%), PTA (16%),
PTA+atherectomy (4%), atherectomy (4%), unspeciﬁed (4%), and PTA+stent+
atherectomy (1%). At 24-months post-procedure (N¼3,721), the atherectomy group
had the lowest mean healthcare costs ($49,588) while bypass had the highest
($62,340). After controlling for covariates, there were no statistically signiﬁcant dif-
ferences between atherectomy and any of the other treatments with respect to all-cause
health care costs over 24 months. Atherectomy patients were also not statistically
signiﬁcantly more likely than any of the other therapies to be hospitalized during
follow-up.
Conclusions: Diabetics tend to have a higher re-stenosis rate and are thought to have
more complex disease versus non-diabetic patients. Among PAD patients with dia-
betes in this large claims database, directional atherectomy was associated with similar
re-hospitalization rates and similar or lower costs compared to other PAD therapies
over 24 months.Thrombectomy
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Background: Patients with ST-elevation myocardial infarction (STEMI) treated
with primary angioplasty tend to have worse procedural results due to the presence of
larger amount of residual intrastent thrombus. However little is known about the
relationship between residual intrastent thrombus and clinical outcome. Aim of the
present study was to explore the correlation between the amount of residual intrastent
thrombus burden and the clinical outcome in patients enrolled in the randomized
COCTAIL II trial
Methods: The study population consisted of 128 STEMI patients who underwent
primary PCI within 6 h from onset of chest pain and randomized to one of the
following four treatments: local infusion of abciximab delivered by the ClearWay with
(group 1) or without thrombectomy (group 2), intracoronary abciximab with (group 3)
or without thrombectomy (group 4). Residual intrastent thrombus burden at OCT
assessment was deﬁned as: number of cross section with residual thrombus
area >10% and mean Thrombus area % (average of % thrombus area in all stented
cross sections). All patients had a clinical assessment at a mean follow-up of 12  4
months./Suppl B j September 13–17, 2014 j TCT Abstracts/Thrombectomy
